Core Insights - Contineum Therapeutics, Inc. reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS) [1] - The trial showed acceptable safety and tolerability but did not meet its primary or secondary efficacy endpoints [2] - The company plans to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal [3] Trial Results - The trial did not show significant changes in binocular 2.5% low contrast letter acuity across treatment arms in RRMS patients [2] - RBC Capital Markets noted that the trial was high risk compared to other programs due to limited evidence, despite some preclinical rationale [4] Future Plans - The company initiated a global Phase 2 clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in Q4 2025 [5] - The initiation of PIPE-791 PrMS and CTX-343 clinical development efforts has been deferred, extending the projected cash runway through 2028 [5] Market Reaction - Following the trial results, CTNM stock decreased by 13.26%, trading at $10.60 [6]